CSF3 and myelodysplastic syndrome: In this cohort of 2114 MDS patients, a 1.6‐fold and twofold increased risk for myocardial infarction and stroke, respectively, was associated with ESA treatment, but no information on the concomitant use of G‐CSF was provided and this effect was not controlled for anemia, an important confounder [14].